SPR-397, 0.25% Ophthalmic Solution May Break the Inflammatory Cycle of Dry Eye Disease

被引：0
|
作者：
Crean, Christopher [1 ]
Dixon, Angela [1 ]
Cousin, Wendy [2 ]
Somaratne, Ransi [2 ]
机构：
[1] Xyzagen, Pittsboro, NC USA
[2] Spring Discovery, Palo Alto, CA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
    Li, Jing-Xing
    Tsai, Yi-Yu
    Lai, Chun-Ting
    Li, You-Ling
    Wu, Ying-Hsuen
    Chiang, Chun-Chi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
  • [42] A Novel Ophthalmic Solution Containing Glicopro® Complex for the Treatment of Patients with Dry Eye Disease: Results from a Pilot Study
    Giannaccare, Giuseppe
    Vaccaro, Sabrina
    Borselli, Massimiliano
    Rossi, Costanza
    Carnovale Scalzo, Giovanna
    Scalia, Giovanni
    Di Cesare Mannelli, Lorenzo
    Ghelardini, Carla
    Zerillo, Lucrezia
    Polvere, Immacolata
    Vito, Pasquale
    Zotti, Tiziana
    Stilo, Romania
    Scorcia, Vincenzo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [43] Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study
    Eom, Youngsub
    Kim, Hyo Myung
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2021, 14 (10) : 1518 - 1526
  • [44] Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Patients With Dry Eye Disease Associated With Ocular Graft-Versus-Host Disease
    Wong, Calvin W.
    Le, Harrison L.
    Gombos, Dan S.
    Yee, Richard W.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [45] Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
    Burade, Vinod
    Zalawadia, Rishit
    Patel, Alpesh
    Ogundele, Abayomi
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 2747 - 2755
  • [46] Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: combined evidence from 5 randomized controlled trials.
    Shojaei, Amir
    Darvish-Zargar, Mahshad
    Holland, Edward J.
    Chan, Clara
    Nichols, Kelly K.
    Tauber, Joseph
    Baudouin, Christophe
    Raychaudhuri, Aparna
    Roy, Monica
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [47] Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice
    Fu, Rongrong
    Jiang, Yanhua
    Zhou, Jing
    Zhang, Jinsong
    MOLECULAR MEDICINE REPORTS, 2019, 19 (05) : 4011 - 4018
  • [48] Performance and Safety of a Sodium Hyaluronate, Xanthan Gum, and Osmoprotectants Ophthalmic Solution in the Treatment of Dry Eye Disease: An Observational Clinical Investigation
    Senosiain, Mercedes Molero
    Burgos-Blasco, Barbara
    Perez-Garcia, Pilar
    Sanchez-Ventosa, Alvaro
    Villalba-Gonzalez, Marta
    Perez, Maria Dolores Lopez
    Diaz, Jose Carlos
    Diaz-Mesa, Vanesa
    Cuadrado, Alberto Villarrubia
    Elordi, Enrique Artiaga
    Poves, Jose Manuel Larrosa
    Blasco, Alejandro
    Mateo, Antonio
    Civiale, Claudine
    Bonino, Laura
    Cano-Ortiz, Antonio
    OPHTHALMOLOGY AND THERAPY, 2025, : 675 - 692
  • [49] Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies
    Korenfeld, Michael
    Nichols, Kelly K.
    Goldberg, Damien
    Evans, David
    Sall, Ken
    Foulks, Gary
    Coultas, Susan
    Brazzell, Kim
    CORNEA, 2021, 40 (05) : 564 - 570
  • [50] A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease
    Goldberg, Damien F.
    Malhotra, Ranjan P.
    Schechter, Barry A.
    Justice, Angela
    Weiss, Sidney L.
    Sheppard, John D.
    OPHTHALMOLOGY, 2019, 126 (09) : 1230 - 1237
12345